A Study of LY2623091 in Participants With High Blood Pressure

A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of LY2623091 in Patients With Primary Hypertension

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.

Inclusion Criteria:

• Have a history of hypertension.

• If participants are naïve to treatment of hypertension, or have not been treated with any antihypertensive medications within the 30 days immediately prior to screening:

  • Have seated systolic (SBP) of ≥140 and <170 millimeters of mercury (mmHg) at screening and at the end of the lead-in period.

• If participants are currently being treated for hypertension:

  • Are taking a stable dose of 1 or 2 antihypertensive medications for at least the previous 30 days. A combination antihypertensive medication from 2 classes is considered as 2 antihypertensive medications.
  • Are willing to discontinue the antihypertensive medications during the study.
  • Have seated SBP of ≥140 and <170 mmHg at the end of the lead-in period.

• Have a body mass index (BMI) ≥18.5 and <40 kilograms/m^2.

Exclusion Criteria:

• Have a history of severe hypertension (defined as SBP ≥180 mmHg and/or diastolic (DBP) ≥120 mmHg), secondary hypertension, symptomatic postural hypotension, or hospitalization due to hypertension.
• Have SBP ≥180 mmHg and/or DBP ≥110 mmHg at screening, lead-in period, or randomization.
• Have a history of hospitalization due to hyperkalemia, or history of drug discontinuation due to elevated serum potassium levels.
• Have a serum potassium ≤3.5 or >5.0 millimoles per liter (mmol/L).
• Have an estimated glomerular filtration rate (eGFR) <50 milliliters/minute/1.73 m^2.